Most Recent
AstraZeneca has attacked generic drugmaker Pharmacor’s challenge to a patent extension for its diabetes drug Forxiga, telling a judge that it hinges on the false notion that the protected IP is limited to a single molecule.
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
The ACCC has appealed a judge's dismissal of its case against mail-order catalogue business Magnamail after finding representations that customers could win major prizes if they ordered from its catalogues were true.
Fashion retailer City Beach has lost an appeal of a $14 million penalty secured by the consumer regulator in the first enforcement action for breaches of button battery safety standards.
Magnamail has defeated an ACCC suit alleging it misled customers by representing they were eligible for major prizes if they ordered from its catalogues, with a judge finding the mail order company's representation that customers 'could' win major prizes was true.
Mail order company Magnamail has denied allegations by the Australian Competition and Consumer Commission that it sent false or misleading promotional material implying customers were eligible for major prizes if they ordered from its catalogues.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.
A recent judgment that clarified the date for assessing best method knowledge for divisional patents appears to create new difficulties for patent applicants, lawyers say.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.